Additional file 3: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Figure S1. MerTK knockdown mediated by shMerTK 4 suppressed downstream signaling pathways and proliferation in MCL cells. Figure S2. MerTK inhibition by either shRNA or treatment with UNC2250 suppressed migration of MCL cells. Figure S3. The effects of UNC2250 on proliferation and apoptosis of MCL cells. Figure S4. Representative flow cytometry profiles for apoptosis assays in Z-138, Mino and JVM-2 cells. Figure S5. Representative flow cytometry profiles for cell cycle analysis in Z-138, Mino and JVM-2 cells. Figure S6. Proliferation of Z-138 and Mino cells was inhibited with increasing concentrations of vincristine or doxorubicin. Figure S7. Expression of microRNA-126, microRNA-335 and Gas6 in MCL cells. (DOCX 15 kb

Additional file 2: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Supplementary Methods: Confocal immunofluorescence assays; RNA extraction, reverse transcription and Real-Time PCR. (DOCX 2252 kb

Additional file 3: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Supplementary method. The synthesis details of BK011. (DOCX 13 kb

Additional file 1: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Table S1. Baseline characteristics of MCL patients receiving R-CHOP like regimens and their correlations with MerTK. Table S2. Information of antibodies applied in immunohistochemistry and western blot assays. Table S3. Combination index values of UNC2250 and Vincristine or Doxorubicin in Z-138 and Mino cells. (DOCX 28 kb

Additional file 7: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S4. The clinicalpathological characteristics of xenografts. (DOCX 14 kb

Additional file 1: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S1. The distribution of Q20 and Q30 representing quality control of sequencing. (DOCX 14 kb

Additional file 8: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S5. Summary of SNVs, InDels, CNVs, and fusions of the 50 xenografts by targeted sequencing. (DOCX 14 kb

Additional file 9: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S6. The expression of PD-L1 in EBV-positive and EBV-negative xenografts. (DOCX 12 kb

Additional file 2: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Figure S1. The work flow of gene variation calling. (DOCX 195 kb

Additional file 6: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S3. The list of genes sequenced in this study. (DOCX 16 kb